
Sign up to save your podcasts
Or


Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By Andreessen Horowitz, a16z Bio + Health4.5
149149 ratings
Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

1,296 Listeners

536 Listeners

1,993 Listeners

1,105 Listeners

2,342 Listeners

3,992 Listeners

233 Listeners

337 Listeners

104 Listeners

10,254 Listeners

551 Listeners

25 Listeners

171 Listeners

300 Listeners

61 Listeners

475 Listeners

34 Listeners

42 Listeners